Doorgaan naar hoofdnavigatie
Doorgaan naar zoeken
Ga verder naar hoofdinhoud
Sorteer per
Keyphrases
Pharmacokinetics
56%
Therapeutic Drug Monitoring
31%
Population Pharmacokinetics (PopPK)
21%
Liquid Chromatography-tandem Mass Spectrometry (LC-MS/MS)
17%
Olaparib
12%
Pediatric Oncology
11%
Population Pharmacokinetic Modeling
10%
Alectinib
10%
Human Plasma
10%
Cytochrome P450 3A4 (CYP3A4)
10%
95% Confidence Interval
10%
Exposure Modeling
9%
Abiraterone
9%
Treatment Outcome
9%
Physiologically-based Pharmacokinetic Model
9%
Cisplatin
8%
Non-small Cell Lung Cancer (NSCLC)
8%
Chemotherapy
8%
Plasma Concentration
8%
Overall Survival
8%
Pharmacokinetic Study
8%
Pemetrexed
7%
Pediatric
7%
Oncology
7%
Clinical Practice
7%
Pediatric Patients
7%
High Performance Liquid Chromatography-tandem Mass Spectrometry (HPLC-MS/MS)
7%
Human Serum
7%
Proof of Concept Study
7%
Mass Spectrometry Methods
7%
Pharmacodynamics
7%
Adverse Events
6%
Sunitinib
6%
Carboplatin
6%
Imatinib
6%
Non-small Cell Lung Cancer Patients
6%
Oral Anticancer Agents
6%
Meta-analysis
6%
Phase I Study
6%
Clinical Outcomes
5%
Visceral Leishmaniasis
5%
Children with Cancer
5%
Drug Interactions
5%
Lorlatinib
5%
Sodium Thiosulfate
5%
Kinase Inhibitor
5%
Gallium-68
5%
Neonate
5%
MS Method
5%
Breast Milk
5%
Randomized Controlled Trial
5%
Lutetium-177 (177Lu)
5%
Dose Adjustment
5%
Volumetric Absorptive Microsampling
5%
Drug Use
5%
Prostate Cancer Patients
5%
Renal Function
5%
Anticancer Drugs
5%
Pharmacology, Toxicology and Pharmaceutical Science
Pharmacokinetics
100%
Therapeutic Drug Monitoring
28%
Chemotherapy Regimens
15%
Anticarcinogen
15%
Olaparib
13%
Malignant Neoplasm
13%
Pharmacodynamics
13%
Non Small Cell Lung Cancer
11%
Neoplasm
11%
Adverse Event
10%
Alectinib
10%
Cisplatin
9%
Biological Marker
9%
Pharmacokinetic Modeling
8%
Visceral Leishmaniasis
8%
Imatinib
8%
Abiraterone
8%
Overall Survival
8%
Vincristine
7%
Sunitinib
7%
Pemetrexed
7%
CYP3A4
7%
Gallium 68
7%
Carboplatin
7%
Progression Free Survival
6%
Diseases
6%
Clinical Trial
6%
Phosphotransferase Inhibitor
6%
Breast Cancer
6%
Drug-Drug Interaction
6%
Skin Leishmaniasis
5%
Lutetium 177
5%
Sodium Thiosulfate
5%
Gastrointestinal Stromal Tumor
5%
Childhood Cancer
5%
Clinical Study
5%
Lorlatinib
5%
Paclitaxel
5%
Cmin
5%